WO2002096442A1 - Utilisation d'un produit contenant un extrait de catuama en tant qu'agent antidepresseur et pour lutter contre les troubles de l'anxiete - Google Patents

Utilisation d'un produit contenant un extrait de catuama en tant qu'agent antidepresseur et pour lutter contre les troubles de l'anxiete Download PDF

Info

Publication number
WO2002096442A1
WO2002096442A1 PCT/BR2001/000092 BR0100092W WO02096442A1 WO 2002096442 A1 WO2002096442 A1 WO 2002096442A1 BR 0100092 W BR0100092 W BR 0100092W WO 02096442 A1 WO02096442 A1 WO 02096442A1
Authority
WO
WIPO (PCT)
Prior art keywords
product
extract
catuama
treatment
trichilia
Prior art date
Application number
PCT/BR2001/000092
Other languages
English (en)
Inventor
Osvaldo Silva Filho
Tadafissa Fujii
João BATISTA CALIXTO
Leslei Bauermann Bortolanza
Maria Martha Campos
Original Assignee
Laboratorio Catarinense S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorio Catarinense S.A. filed Critical Laboratorio Catarinense S.A.
Publication of WO2002096442A1 publication Critical patent/WO2002096442A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/58—Meliaceae (Chinaberry or Mahogany family), e.g. Azadirachta (neem)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • the present invention relates to the use of a product comprising Catuama extract, comprising species of Trichilia sp., particularly Trichilia catigua (Meliaceae), Paullinia cupana (Sapindaceae), Ptychopetalum olacoides (Olacaceae) and Zingiber officinale (Zingiberaceae).
  • Trichilia catigua Meliaceae
  • Paullinia cupana Sapindaceae
  • Ptychopetalum olacoides Ole
  • Zingiberaceae Zingiber officinale
  • Medicinal plants known as catuaba have recognized uses due to their aphrodisiac activities, as a tonic and in the treatment of physical and mental fatigue.
  • phytotherapeutic formulations prepared from extracts of catuaba plants which can be used alone or in combination with other medicinal plant extracts, such as guarana.
  • a number of alternative formulations containing extracts of other species of catuaba are already well-known from the state-of-the-art, all of them being related to the tonic and stimulating effect of this group of plants.
  • phytotherapeutic products comprising a combination of extracts of plants from the Trichilia sp.
  • Trichilia catigua Meliaceae
  • Paullinia cupana Sapindaceae
  • Ptychopetalum olacoides Olacaceae
  • Zingiber officinale Zingiberaceae
  • Catuama® A commercially available product comprising extracts of the above-mentioned plants in combination with suitable carriers is Catuama®. More particularly, Catuama® is a phytotherapeutical widely used in Brazil. Its composition consists of 4 extracts from medicinal plants including: catuaba (Trichilia catigua, A. juss, Meliaceae - (husk)), guarana (Paullinia cupana, K., Sapinadaceae - (seed)), muirapuama (Ptychopetalum olacoides, B., Olacaceae - (root)) and ginger (Zingiber officinale, L., Zingiberaceae - (rhizome)). Summary of the Invention
  • the present invention refers to the use of a product of the extract of Catuama comprising Trichilia sp., particularly Trichilia catigua (Meliaceae),
  • Zingiber officinale Zingiberaceae
  • Zingiberaceae as an agent in the treatment or preven- tion of depression and/or anxiety disorders.
  • this invention refers to pharmaceutical compositions comprising said extracts having activities in the treatment or prevention of depression and/or anxiety disorders.
  • this invention refers to a method for the treatment or prevention of depression and/or anxiety disorders using said extract of Catuama.
  • the invention refers to the use of a product comprising extract of Trichilia sp., particularly Trichilia catigua (Meliaceae), Paullinia cupana (Sapindaceae), Ptychopetalum olacoides (Olacaceae) and Zingiber officinale (Zingiberaceae), for preparing a pharmaceutical composition for the treatment or prevention of depression and/or anxiety di sorders.
  • Trichilia sp. particularly Trichilia catigua (Meliaceae), Paullinia cupana (Sapindaceae), Ptychopetalum olacoides (Olacaceae) and Zingiber officinale (Zingiberaceae)
  • the extract of Catuama comprising of Trichilia sp., particularly Trichilia catigua (Melia- ceae), Paullinia cupana (Sapindaceae), Ptychopetalum olacoides (Olacaceae) and Zingiber officinale (Zingiberaceae), has extraordinary antidepres- sive and anxiolytic activities.
  • antidepressive and anxiolytic activities includes activities related to disorders such as: light or moderate depression, associ- ated with anxiety conditions or not; agitation and irritability, or other symptoms present during premenstrual syndrome, including migraine; depression resulting from chronic pain conditions, including those seen in somatic dis- eases accompanied by neuropathic pain; unsociability; psychoipathic, neu ⁇ rotic or reactive mood disorders; control of conditions related to panic syn ⁇ drome; difficulties with daily activities and behavior disorders.
  • disorders such as: light or moderate depression, associ- ated with anxiety conditions or not; agitation and irritability, or other symptoms present during premenstrual syndrome, including migraine; depression resulting from chronic pain conditions, including those seen in somatic dis- eases accompanied by neuropathic pain; unsociability; psychoipathic, neu ⁇ rotic or reactive mood disorders; control of conditions related to panic syn ⁇ drome; difficulties with daily activities and behavior disorders.
  • a number of products comprising varying concentrations of extract of the above plants are commercially available.
  • the use thereof so far recommended in the art is related to the treatment of physical and mental fatigues, neuromuscular asthenia and weariness.
  • composition of the present invention contains as follows:
  • Extract of Trichilia sp (specially Trichi0.50 to 5.50 0.50 to 5.0 lia catigua)
  • Extract of Ptychopetalum olacoides 0.01 to 5.50 0.01 to 5.0
  • Extract of Zingiber officinale 0.10 to 2.00 0.1 to 0.40
  • Extract of Trichilia sp (specially Trichilia 5 to 50 30 to 50 catigua)
  • extract of Catuama comprises:
  • the product may comprise usual excipients for formulation such as preservatives, colorants, carriers etc. Adequate excipients are well known by those skilled in the art and do not constitute limiting aspects of the inven- tion.
  • Trichilia catigua A. Juss.
  • T. claus- seni C. DC T. casaretti C. DC
  • T. pallida Swartz. T. elegans A. Juss.
  • the materials extracted from Trichilia sp. are preferably fragments of the whole plant, more preferably stalk, which are advantageously used as extract, more preferably they are formulated with pharmaceutically acceptable inert carriers.
  • Formu- lations of Trichilia sp. useful for the present invention can be administered, e.g., orally in the form of tablets, coated tablets, hard and soft gelatin capsules, solutions, emulsions and suspensions; or rectally, in the form of suppositories.
  • Suitable carriers include, but are not limited to, lactose, starch or derivatives thereof, talc, stearic acid or salts thereof in the case of solid for- mulations for oral administration.
  • Suitable carriers for soft gelatin capsules include vegetable oils, waxes, fats, semi-solid and liquid polyols. Solutions may be prepared comprising selected carriers such as water, polyols and carbohydrates.
  • suitable carriers comprise natural or hardened oils, waxes, fats and polyols.
  • the formulations of the Catuama extract according to the present invention may contain preservative agents, solubilizing agents, stabilizers, wetting agents, emulsifiers, sweeteners, coloring agents, flavoring agents, tonicity adjustment substances, buffers, coating agents or anti-oxidants.
  • an effective dosage for administration to humans was found to be in the range from 10 mg to 0.5 g Catuama extract.
  • the invention will now be described specifically referring to the applicant's product having the name Catuama®, that is already commercialized in Brazil for the treatment of several chronic diseases such as physical and mental fatigue, neuromuscular asthenia and weariness.
  • the pharma- ceutical formulations available allow the product to be administered orally.
  • Another advantage of the product is associated to the lack of any reported undesirable or side effects, even when the product is used for long periods of time.
  • Catuama extract referred to in this invention (specially Catauma®) exhibits antidepres- sant and anxiolytic effects, specially when used regularly and for extended periods of time.
  • the present invention relates to the Catauma extract effects on pathologies involving changes in the central nervous system, essentially for the treatment or prevention of depressive disorders related to anxiety or not.
  • Substances acting centrally such as those contained in Catuama extract (particularly Catuama ® ) could be highly useful when administered in combination with each other, by virtue of its synergistic effects.
  • Synergism is defined as the effect arising from the association of low doses of two or more substances exhibiting the same effect. This concept is particularly important when taking into account the reduction of undesirable effects of such substances.
  • Catuama extract especially Catuama®
  • the four plants that comprise the product have antidepressive and anxiolytic ef ⁇ fects that are potentiated when the extracts are used in combination.
  • Modulation of the response mediated in the central nervous system can be quite interesting for the treatment of diseases such as light and moderate depression.
  • Depressive disorders can be described as multi- causal ones and are known for triggering a series of other relevant changes, which need to be considered when developing a new antidepressant.
  • depression occurs in conjunction with other disorders, such as anxiety, and agitation states.
  • depression may be a consequence of an- other pathologic condition, including those such as neuropathic pain, associated with somatic diseases.
  • Catuama extract specially Catuama®
  • Figure 1 shows the effect of acute treatment with Catuama extract on the immobility time in the compelled swimming test in mice. Each group represents the average of 8 to 10 animals and the vertical bars indicate the E.P.M. It significantly differs from the control group, **P ⁇ 0.01.
  • Figure 2 shows the effect of subchronic treatment with Catuama extract on the immobility time in the compelled swimming test in mice. Each group represents the average of 8 to 10 animals and the vertical bars indicate the E.P.M. It significantly differs from the control group, **P ⁇ 0.01.
  • Figure 3 shows the effect of chronic treatment with Catuama ex- tract on the immobility time in the compelled swimming test in mice. Each group represents the average of 8 to 10 animals and the vertical bars indicate the E.P.M. It significantly differs from the control group, **P ⁇ 0.01.
  • Figure 4 shows the effect of acute treatment with Catuama extract (1-500 ⁇ g/ml) on locomotion in the open field test in mice. Each group represents the average of 8 to 10 animals and the vertical bars indicate the E.P.M. It significantly differs from the control group, ** P ⁇ 0.01.
  • the illustrative test examples below are given for a better description of the present invention. However, the data and procedures illustrated herein refer to certain embodiments of the present invention and are not to be construed as limiting the scope thereof.
  • Catuama extract a composition of ex- tracts in the solid and dry form as follows:
  • mice 25-30 g were indi- vidually placed inside a cylindrical container (10 cm diameter x 25 cm height) containing 19 cm of water at 25 ⁇ 1°C. The time of immobility of the animals were measured during a 6 minute period. The animals were treated with Catuama extract (at doses of 300 mg/kg or more, orally, 6 hours before). In another series of experiments, in order to verify the chronic effect of the product, the mice were treated with Catuama extract for 7 days, at doses of up to 200 mg/kg, orally. Other control animals were pre-treated with saline and served as controls.
  • mice Male mice (25 - 30 g) were used for carrying out these experi- ments. The animals were lifted by their tail with the aid of adhesive tape and the time of immobility was measured for a 6 minute period. The mice were treated with Catuama extract (at doses of 300 mg/kg or more, v.o., 6 hours before). The control animals were pre-treated with saline. Another group of animals received imipramine (15 mg/kg, i.p., 30 minutes before), which was used as a positive control as previously described.
  • mice were subjected to the open field test. Mice were indi- vidually placed inside a box (40 x 50 x 60 cm height) with the floor divided into 12 identical squares. The number of crossed squares (with the 4 paws) was recorded during a 6 minute period. The mice were treated with Catuama extract (at varying doses of up to 300 mg/kg, v.o., 6 hours before). The animals of the control group were pre-treated with saline.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne l'utilisation d'un produit à base d'extrait de Catuama comprenant les espèces Trichilia sp. (de préférence, Trichilia catigua), Paullinia cupana Sapindaceae, Ptychopetalum olacoides Olacaceae et Zingiber officinale Zingiberaceae. Ce produit est un antidépresseur et un agent anxiolytique. Cette invention concerne tout particulièrement un extrait de Catuama disponible dans le commerce sous le nom de Catuama®.
PCT/BR2001/000092 2001-05-30 2001-07-31 Utilisation d'un produit contenant un extrait de catuama en tant qu'agent antidepresseur et pour lutter contre les troubles de l'anxiete WO2002096442A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR0102184-2A BR0102184A (pt) 2001-05-30 2001-05-30 Uso de produto compreendendo extrato de catuama como agente antidepressivo e nos distúrbios da ansiedade, composição farmacêutica compreendendo tal produto para tratamento ou prevenção da depressão e/ou distúrbios da ansiedade, método para tratamento ou prevenção da depressão e/ou distúrbios da ansiedade usando o referido produto e uso do referido produto para produção de uma composição farmacêutica para tratamento ou prevenção da depressão e/ou distúrbios da ansiedade
BRPI0102184-2 2001-05-30

Publications (1)

Publication Number Publication Date
WO2002096442A1 true WO2002096442A1 (fr) 2002-12-05

Family

ID=3947379

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2001/000092 WO2002096442A1 (fr) 2001-05-30 2001-07-31 Utilisation d'un produit contenant un extrait de catuama en tant qu'agent antidepresseur et pour lutter contre les troubles de l'anxiete

Country Status (2)

Country Link
BR (1) BR0102184A (fr)
WO (1) WO2002096442A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501808A (ja) * 2003-08-08 2007-02-01 ラボラトリオ・カタリネンセ・ソシエダデ・アノニマ 心室細動の反転／対処および／または予防のための、トリキリア種の植物原料を単独で、または他の植物の抽出物と組み合わせて含む医薬組成物
PL422894A1 (pl) * 2017-09-16 2019-03-25 Szkoła Główna Gospodarstwa Wiejskiego w Warszawie Sposób wytwarzania naturalnego preparatu ziołowego i preparat ziołowy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002172A1 (fr) * 1997-07-10 1999-01-21 Laboratório Catarinense S/A. FORMULATIONS PHARMACEUTIQUES COMPRENANT UN MATERIAU VEGETAL SELECTIONNE A PARTIR DE $i(TRICHILIA)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999002172A1 (fr) * 1997-07-10 1999-01-21 Laboratório Catarinense S/A. FORMULATIONS PHARMACEUTIQUES COMPRENANT UN MATERIAU VEGETAL SELECTIONNE A PARTIR DE $i(TRICHILIA)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CALIXTO J B ET AL: "HERBAL MEDICINE CATUAMA INDUCES ENDOTHELIUM-DEPENDENT AND -INDEPENDENT VASORELAXANT ACTION ON ISOLATED VESSELS FROM RATS, GUINEA-PIGS AND RABBITS", PHYTOTHERAPY RESEARCH, JOHN WILEY & SONS LTD. CHICHESTER, GB, vol. 11, no. 1, 1 February 1997 (1997-02-01), pages 32 - 38, XP002061880, ISSN: 0951-418X *
VAZ Z R ET AL: "ANALGESIC EFFECT OF THE HERBAL MEDICINE CATUAMA IN THERMAL AND CHEMICAL MODELS OF NOCICEPTION IN MICE", PHYTOTHERAPY RESEARCH, JOHN WILEY & SONS LTD. CHICHESTER, GB, vol. 11, no. 2, 1 March 1997 (1997-03-01), pages 101 - 106, XP002061879, ISSN: 0951-418X *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007501808A (ja) * 2003-08-08 2007-02-01 ラボラトリオ・カタリネンセ・ソシエダデ・アノニマ 心室細動の反転／対処および／または予防のための、トリキリア種の植物原料を単独で、または他の植物の抽出物と組み合わせて含む医薬組成物
JP4689607B2 (ja) * 2003-08-08 2011-05-25 ラボラトリオ・カタリネンセ・ソシエダデ・アノニマ 心室細動の反転／対処および／または予防のための、トリキリア種の植物原料を単独で、または他の植物の抽出物と組み合わせて含む医薬組成物
PL422894A1 (pl) * 2017-09-16 2019-03-25 Szkoła Główna Gospodarstwa Wiejskiego w Warszawie Sposób wytwarzania naturalnego preparatu ziołowego i preparat ziołowy
PL238576B1 (pl) * 2017-09-16 2021-09-06 Szkola Glowna Gospodarstwa Wiejskiego W Warszawie Sposób wytwarzania naturalnego preparatu ziołowego i preparat ziołowy

Also Published As

Publication number Publication date
BR0102184A (pt) 2003-02-04

Similar Documents

Publication Publication Date Title
JP2024010025A (ja) 肝臓の治療および肝臓の健康維持のための組成物、方法および医薬組成物
US20160000845A1 (en) Extract of trigonella foenum-graecum
US20080124413A1 (en) Novel composition containing extracts of butyrospermum parkii and the use of such a composition for preparing a medicament or a dietary supplement for the treatment or prevention of inflammation hypersensitivity or pain
Pearl et al. Herbs in epilepsy: evidence for efficacy, toxicity, and interactions
JP2002518438A (ja) 不安状態または鬱病による神経および行動変化の予防および／または治療のための神経保護組成物
JP2010530841A (ja) 選択的セロトニン再取り込み阻害組成物およびその方法
US11986506B2 (en) Dietary supplements for inhibiting PDE5 and increasing cGMP levels
JP4077149B2 (ja) 自律神経機能向上剤
Belkhodja et al. In vitro and in vivo anti-inflammatory potential of eucalyptus globulus essential oil
Seriki et al. Analysis of phytoconstituents of Desmodium adscendens in relation to its therapeutic properties
KR101999742B1 (ko) 참취 추출물을 유효성분으로 포함하는 신경병증성 통증 예방 또는 치료용 조성물
WO2002096442A1 (fr) Utilisation d'un produit contenant un extrait de catuama en tant qu'agent antidepresseur et pour lutter contre les troubles de l'anxiete
Kotue et al. Ethnobotanicals usages in the management of sickle cell disease (SDC) in some localities of Cameroon
JP2007527358A (ja) ツボクサとゴマを含む、脳の強壮剤としての薬草製剤
Singh et al. Phytotherapy: A novel approach for treating periodontal disease
KR100807758B1 (ko) 항염증 활성을 갖는 미역 추출물
Masihuzzaman et al. Badam shireen (Prunus dulcis Mill): A ghiza-e-dawaee and immunomodulator: A latest review
Hassan Effect of dietary supplementation with tigernut tubers on streptozotocin-induced diabetic rats
Lim et al. Phyllanthus emblica
RU2296579C1 (ru) Средство, обладающее гепатопротекторным и желчегонным действием
KR20040008975A (ko) 뇌기능 및 인지 기능 개선 활성을 갖는 조성물
Qureshi et al. Preclinical safety, anxiolytic and antidepressant activity of Sufoof Jawahar Mohra: a Unani formulation
MX2014008476A (es) Fitocomposicion para el tratamiento de dolores relacionados con enfermedades articulares.
FR2931664A1 (fr) Compositions a base de plantes et utilisations
Alam et al. Ethno-pharmacological and phytochemical study of Rauwolfia serpentina (Asrol)-An extensive review

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP